Clinical and bacteriological evaluation of netilmicin in gram-negative infections. 1977

J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost

A preliminary study was conducted with netilmicin, a new aminoglycoside antibiotic. Its effectiveness was evaluated in vitro against 546 strains of Enterobacteriaceae and Pseudomonas aeruginosa isolated from clinical material. Its effectiveness against gentamicin-susceptible strains was roughly similar to that of gentamicin and other newer aminoglycoside antibiotics. Cross-resistance to netilmicin was found in 9 of 44 gentamicin-resistant strains. A favorable clinical response was observed in 70% of the patients treated with a dose of netilmicin ranging from 4.5 to 7.5 mg/kg. However, the appearance of granular casts was seen in 7 of 10 patients receiving the higher dosage of netilmicin (7.5 mg/kg) and a rise in blood urea nitrogen or serum creatinine levels was observed in 5 of these patients.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D012853 Sisomicin Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS). Sisomycin,Sissomicin,4,5-Dehydrogentamicin,Antibiotic 6640,Extramycin,Pathomycin,Rickamicin,Sch-13475,Siseptin,Sisomicin Sulfate,Sisomicin Sulfate (2:5) Salt,Sizomycin,4,5 Dehydrogentamicin,Sch 13475,Sch13475

Related Publications

J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
April 1976, Journal of clinical pharmacology,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1979, Antimicrobial agents and chemotherapy,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
November 1978, The Journal of antimicrobial chemotherapy,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1979, Canadian Medical Association journal,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
March 1983, The Journal of the Medical Society of New Jersey,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1981, The Mount Sinai journal of medicine, New York,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1981, The American journal of the medical sciences,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
May 1982, The Japanese journal of antibiotics,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1981, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
J Klastersky, and F Meunier-Carpentier, and L Coppens-Kahan, and D Daneau, and J M Prevost
January 1983, Clinical therapeutics,
Copied contents to your clipboard!